How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?

I will focus the conversation here on metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation. Patients with EGFR exon 20 insertion mutations are discussed in a separate question.

The frontline therapy for our involved patient population is osimertinib single agent (less and less used w...

The choice between novel bispecific antibodies and antibody-drug conjugates (ADCs) for EGFR-positive NSCLC patients who have progressed on third-generation EGFR inhibitors is based on several factors. Treatment selection involves analyzing the specific resistance mechanisms present after osimertinib...